Publicaties

1. Appel IM, Kazemier KM, Boos J, Lanvers C, Huijmans J, Veerman AJ, van Wering ER, den Boer ML, Pieters R.
Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia 2008

2. Balgobind BV, Van Vlierberghe P, van den Ouweland AM, Beverloo HB, Terlouw-Kromosoeto JN, van Wering ER, Reinhardt D, Horstmann M, Kaspers GJ, Pieters R, Zwaan CM, Van den Heuvel-Eibrink MM, Meijerink JP.
Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. Blood 2008

3. Blink M, Buitenkamp TD, van Wering ER, Zwaan CM.
Down Syndroom en Leukemie. Down Up (uitgave Stichting Down Syndroom) nr 8, lente 2008.

4. Blink M, van Wering ER, Zwaan CM.
Uw medewerking gevraagd:screening op transiënte myeloproliferatieve ziekte bij pasgeborenen met Down syndroom. Nieuwsbrief NVK, maart 2008.

5. Goemans BF, Zwaan CM, Vijverberg SJ, Loonen AH, Creutzig U, Hahlen K, Reinhardt O, Gibson B, Cloos J and Kaspers GJL.
Large interindividual differences in cellular sensitivity to calicheamin may influence gentuzimab ozogamicin responde in acute myeloid leukemia. Leukemia 2008

6.van Grotel M, Meijerink JP, van Wering ER, Langerak AW, Beverloo HB, Buijs-Gladdines JG, Burger NB, Passier M, van Lieshout EM, Kamps WA, Veerman AJ, van Noesel MM, Pieters R.
Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia 2008

7. van Grotel M, van den Heuvel-Eibrink MM, van Wering ER, van Noesel MM, Kamps WA, Veerman AJ, Pieters R, Meijerink JP.
CD34 expression is associated with poor survival in pediatric T-cell acute lymphoblastic leukemia. Pediatr Blood Cancer 2008

8. Hasle H, Abrahamsson J, Arola M, Karow A, O’Marcaigh A, Reinhardt D, Webb DK, van Wering ER, Zeller B, Zwaan CM, Vyas P.
Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML. Leukemia 2008

9. Larmonie NS, Dik WA, Beverloo HB, van Wering ER, van Dongen JJ, Langerak AW.
BMI1 as oncogenic candidate in a novel TCRB-associated chromosomal aberration in a patient with TCRgammadelta+ T-cell acute lymphoblastic leukemia. Leukemia 2008

10. van Vlierberghe P, van Grotel M, Tchinda J, Lee C, Beverloo HB, van der Spek PJ, Stubbs A, Cools J, Nagata K, Fornerod M, Buijs-Gladdines J, Horstmann M, van Wering ER, Soulier J, Pieters R, Meijerink JP.
The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood 2008

11. van Vlierberghe P, Homminga I, Zuurbier L, Gladdines-Buijs J, van Wering ER, Horstmann M, Beverloo HB, Pieters R, Meijerink JP.
Cooperative genetic defects in TLX3 rearranged pediatric T-ALL. Leukemia 2008

12. van Vlierberghe P, Beverloo HB, Buijs-Gladdines J, van Wering ER, Horstmann M, Pieters R, Meijerink JP.
Monoallelic or biallelic LMO2 expression in relation to the LMO2 rearrangement status in pediatric T-cell acute lymphoblastic leukemia. Leukemia 2008

13. de Vries AC, Langerak AW, Verhaaf B, Niemeyer CM, Stary J, Schmiegelow K, van Wering ER, Zwaan CM, Beishuizen A, Pieters R, van den Heuvel-Eibrink MM. T-cell receptor Vbeta CDR3 oligoclonality frequently occurs in childhood refractory cytopenia (MDS-RC) and severe aplastic anemia. Leukemia 2008

<<Vorige>>

Unless otherwise stated, the content of this page is licensed under Creative Commons Attribution-ShareAlike 3.0 License